Initial Statement of Beneficial Ownership (3)
19 February 2021 - 8:31PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Oliva Robert Letterio |
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/19/2021
|
3. Issuer Name and Ticker or Trading Symbol
Novo Integrated Sciences, Inc. [NVOS]
|
(Last)
(First)
(Middle)
C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
BELLEVUE,, WA 98004
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 178555 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) (1)(2) | 6/29/2015 | 6/29/2023 | Common Stock | 150000 | $1.60 | D | |
Stock Option (right to buy) (2) | 4/28/2017 | 4/28/2024 | Common Stock | 25000 | $1.60 | D | |
Stock Option (right to buy) (2) | 1/26/2021 (3) | 1/25/2026 | Common Stock | 19800 (3) | $3.80 | D | |
Explanation of Responses: |
(1) | Information reported on this Form 3 has been adjusted to give effect to the 1-for-10 reverse stock split of the issuer's common stock, which was effective on February 1, 2021. |
(2) | Represents a grant by the issuer, approved by the issuer's Board of Directors. |
(3) | The grant vests, and becomes exercisable, with respect to 1,650 shares each month, beginning on the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Oliva Robert Letterio C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE,, WA 98004 | X |
|
|
|
Signatures
|
/s/ Christopher David, as Attorney-in-Fact for Robert Oliva | | 2/19/2021 |
**Signature of Reporting Person | Date |